2021
Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies
Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. Clinical Lymphoma Myeloma & Leukemia 2021, 21: e483-e487. PMID: 33551344, DOI: 10.1016/j.clml.2021.01.003.Peer-Reviewed Original Research
2006
Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity
Iwata M, Pillai M, Ramakrishnan A, Hackman R, Deeg H, Opdenakker G, Torok-Storb B. Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity. Blood 2006, 109: 85-92. PMID: 16954500, PMCID: PMC1785081, DOI: 10.1182/blood-2006-05-020289.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBone MarrowCells, CulturedChemokinesCulture Media, ConditionedCytokinesEnzyme InductionFemaleFibroblastsHumansIn Situ Hybridization, FluorescenceLipopolysaccharide ReceptorsMaleMatrix Metalloproteinase 9Middle AgedMonocytesMyelodysplastic SyndromesRecombinant ProteinsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerStromal CellsConceptsMMP-9Myelodysplastic syndromeMarrow cellularityMonocyte populationsMatrix metalloproteinasesGelatinase B/matrix metalloproteinase-9Stromal cellsMCP-1/CCL2IL-8/CXCL8SDF-1/CXCL12Matrix metalloproteinase-9MMP-9 expressionMarker-positive cellsInducible levelsMDS patientsIL-6Healthy donorsMetalloproteinase-9Marrow stromal cellsG-CSFPatientsGM-CSFMonocytesStromal factorsM-CSF